{"transactions":[{"id":2838137,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2021-02-23T23:05:48.000Z","date":"2021-02-20","kind":"tax_withholding","acquired":false,"shares":35672,"price":18.79,"value":670276.88,"ownership":{"direct":true},"balance_after":242499,"source":{"system":"sec-edgar","filing":"0001179110-21-002157","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911021002157/edgar.xml","form_type":"4"}},{"id":2967451,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2020-11-24T23:16:19.000Z","date":"2020-11-20","kind":"tax_withholding","acquired":false,"shares":4639,"price":17.21,"value":79837.19,"ownership":{"direct":true},"balance_after":278171,"source":{"system":"sec-edgar","filing":"0001179110-20-011367","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020011367/edgar.xml","form_type":"4"}},{"id":3006802,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-10-14T16:15:24.000Z","date":"2020-10-13","kind":"disposition_to_issuer","acquired":false,"shares":25453,"price":17.39,"value":442627.67,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option."}],"balance_after":0,"derivative":{"exercise_price":17.11,"underlying":"Common Stock","underlying_shares":25453},"source":{"system":"sec-edgar","filing":"0000899243-20-028178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1607733/000089924320028178/doc4.xml","form_type":"4"}},{"id":3006801,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-10-14T16:15:24.000Z","date":"2020-10-13","kind":"disposition_to_issuer","acquired":false,"shares":13313,"price":34.5,"value":459298.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of to SPN MergerSub, Inc. (\"Merger Sub\"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., (\"Nestle\"), and Merger Sub (the \"Merger Agreement\"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the \"Offer Price\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each Issuer restricted stock unit (\"RSU\") that was outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") vested in full,  terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-028178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607733/000089924320028178/doc4.xml","form_type":"4"}},{"id":3006800,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-10-14T16:15:24.000Z","date":"2020-10-10","kind":"other","acquired":false,"shares":6250,"price":34.5,"value":215625.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-028178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607733/000089924320028178/doc4.xml","form_type":"4"}},{"id":3048390,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2020-08-24T22:21:57.000Z","date":"2020-08-21","kind":"sale","acquired":false,"shares":25000,"price":18.2896,"value":457240.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices from $18.22 to $18.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":282810,"source":{"system":"sec-edgar","filing":"0001179110-20-009263","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020009263/edgar.xml","form_type":"4"}},{"id":3048389,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2020-08-24T22:21:57.000Z","date":"2020-08-20","kind":"tax_withholding","acquired":false,"shares":4646,"price":18.22,"value":84650.12,"ownership":{"direct":true},"balance_after":307810,"source":{"system":"sec-edgar","filing":"0001179110-20-009263","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020009263/edgar.xml","form_type":"4"}},{"id":3130113,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-29T19:17:16.000Z","date":"2020-05-27","kind":"grant","acquired":true,"shares":25453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest and become exercisable as to 1/36th of the shares subject to the option on each monthly anniversary of the grant date, assuming continuous service as a director until each such vesting date."}],"balance_after":25453,"derivative":{"exercise_price":17.11,"expiration_date":"2030-05-26","underlying":"Common Stock","underlying_shares":25453},"source":{"system":"sec-edgar","filing":"0000899243-20-014618","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607733/000089924320014618/doc4.xml","form_type":"4"}},{"id":3130112,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-05-29T19:17:16.000Z","date":"2020-05-27","kind":"grant","acquired":true,"shares":13313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest as to 1/3rd of the RSUs on each anniversary of the grant date, assuming continuous service as a director until each such vesting date."}],"balance_after":19563,"source":{"system":"sec-edgar","filing":"0000899243-20-014618","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607733/000089924320014618/doc4.xml","form_type":"4"}},{"id":3136543,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2020-05-22T22:06:50.000Z","date":"2020-05-20","kind":"tax_withholding","acquired":false,"shares":4212,"price":26.67,"value":112334.04,"ownership":{"direct":true},"balance_after":312456,"source":{"system":"sec-edgar","filing":"0001179110-20-006524","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020006524/edgar.xml","form_type":"4"}},{"id":3252009,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2020-02-25T00:07:07.000Z","date":"2020-02-20","kind":"tax_withholding","acquired":false,"shares":33608,"price":25.9,"value":870447.2,"ownership":{"direct":true},"balance_after":316668,"source":{"system":"sec-edgar","filing":"0001179110-20-002143","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020002143/edgar.xml","form_type":"4"}},{"id":3288127,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2020-02-05T23:57:04.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":54000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 15, 2016, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 3, 2020, the performance conditions applicable to 54,000 shares were achieved and such shares will vest on February 20, 2021, subject to the reporting person's continued service."}],"balance_after":350276,"source":{"system":"sec-edgar","filing":"0001179110-20-001198","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020001198/edgar.xml","form_type":"4"}},{"id":3288126,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2020-02-05T23:57:04.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":296276,"source":{"system":"sec-edgar","filing":"0001179110-20-001198","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020001198/edgar.xml","form_type":"4"}},{"id":3360796,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2019-11-22T23:20:29.000Z","date":"2019-11-20","kind":"tax_withholding","acquired":false,"shares":2692,"price":17.6,"value":47379.2,"ownership":{"direct":true},"balance_after":231276,"source":{"system":"sec-edgar","filing":"0001179110-19-012013","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911019012013/edgar.xml","form_type":"4"}},{"id":3430789,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2019-08-22T22:00:21.000Z","date":"2019-08-20","kind":"tax_withholding","acquired":false,"shares":2710,"price":21.51,"value":58292.1,"ownership":{"direct":true},"balance_after":233968,"source":{"system":"sec-edgar","filing":"0001179110-19-009785","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911019009785/edgar.xml","form_type":"4"}},{"id":3514654,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2019-05-22T22:05:49.000Z","date":"2019-05-20","kind":"tax_withholding","acquired":false,"shares":2705,"price":19.84,"value":53667.2,"ownership":{"direct":true},"balance_after":236678,"source":{"system":"sec-edgar","filing":"0001179110-19-006520","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911019006520/edgar.xml","form_type":"4"}},{"id":3638115,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2019-02-22T23:13:31.000Z","date":"2019-02-20","kind":"tax_withholding","acquired":false,"shares":7778,"price":27,"value":210006.0,"ownership":{"direct":true},"balance_after":239383,"source":{"system":"sec-edgar","filing":"0001179110-19-002409","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911019002409/edgar.xml","form_type":"4"}},{"id":3670046,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinay Shares","published_at":"2019-02-07T22:43:13.000Z","date":"2019-02-05","kind":"grant","acquired":true,"shares":47250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 15, 2016, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 5, 2019, the performance conditions applicable to 47,250 shares were achieved and such shares will vest on February 20, 2020, subject to the reporting person's continued service."}],"balance_after":247161,"source":{"system":"sec-edgar","filing":"0001179110-19-001558","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911019001558/edgar.xml","form_type":"4"}},{"id":3670045,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2019-02-07T22:43:13.000Z","date":"2019-02-05","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":199911,"source":{"system":"sec-edgar","filing":"0001179110-19-001558","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911019001558/edgar.xml","form_type":"4"}},{"id":3754215,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2018-11-21T22:43:11.000Z","date":"2018-11-20","kind":"tax_withholding","acquired":false,"shares":7368,"price":24.79,"value":182652.72,"ownership":{"direct":true},"balance_after":134911,"source":{"system":"sec-edgar","filing":"0001179110-18-013106","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911018013106/edgar.xml","form_type":"4"}},{"id":3835536,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2018-08-22T23:33:06.000Z","date":"2018-08-20","kind":"tax_withholding","acquired":false,"shares":6683,"price":26.95,"value":180106.85,"ownership":{"direct":true},"balance_after":142279,"source":{"system":"sec-edgar","filing":"0001179110-18-010818","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911018010818/edgar.xml","form_type":"4"}},{"id":3921626,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2018-05-22T23:01:26.000Z","date":"2018-05-20","kind":"tax_withholding","acquired":false,"shares":26991,"price":24.31,"value":656151.21,"ownership":{"direct":true},"balance_after":148962,"source":{"system":"sec-edgar","filing":"0001179110-18-007371","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911018007371/edgar.xml","form_type":"4"}},{"id":3930233,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2018-05-16T23:03:34.000Z","date":"2018-05-14","kind":"grant","acquired":true,"shares":33750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On May 14, 2018, the performance conditions applicable to 33,750 shares were achieved and such shares will vest on May 20, 2018."}],"balance_after":175953,"source":{"system":"sec-edgar","filing":"0001179110-18-006935","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911018006935/edgar.xml","form_type":"4"}},{"id":4039496,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2018-02-22T22:39:11.000Z","date":"2018-02-20","kind":"tax_withholding","acquired":false,"shares":8293,"price":29.09,"value":241243.37,"ownership":{"direct":true},"balance_after":142203,"source":{"system":"sec-edgar","filing":"0001179110-18-002607","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911018002607/edgar.xml","form_type":"4"}},{"id":4057125,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2018-02-14T23:20:11.000Z","date":"2018-02-12","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":150496,"source":{"system":"sec-edgar","filing":"0001179110-18-002122","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911018002122/edgar.xml","form_type":"4"}},{"id":4152183,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2017-11-22T21:37:39.000Z","date":"2017-11-20","kind":"tax_withholding","acquired":false,"shares":7846,"price":28.58,"value":224238.68,"ownership":{"direct":true},"balance_after":141496,"source":{"system":"sec-edgar","filing":"0001179110-17-014562","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911017014562/edgar.xml","form_type":"4"}},{"id":4227273,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2017-08-22T22:28:07.000Z","date":"2017-08-20","kind":"tax_withholding","acquired":false,"shares":7064,"price":27.4,"value":193553.6,"ownership":{"direct":true},"balance_after":149342,"source":{"system":"sec-edgar","filing":"0001179110-17-011747","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911017011747/edgar.xml","form_type":"4"}},{"id":4307774,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2017-05-23T23:59:18.000Z","date":"2017-05-20","kind":"tax_withholding","acquired":false,"shares":7065,"price":36.83,"value":260203.95,"ownership":{"direct":true},"balance_after":156406,"source":{"system":"sec-edgar","filing":"0001179110-17-007877","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911017007877/edgar.xml","form_type":"4"}},{"id":4394310,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2017-03-08T23:11:27.000Z","date":"2017-03-07","kind":"sale","acquired":false,"shares":424,"price":30.8,"value":13059.2,"ownership":{"direct":true},"balance_after":163471,"source":{"system":"sec-edgar","filing":"0001179110-17-004273","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911017004273/edgar.xml","form_type":"4"}},{"id":4394309,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2017-03-08T23:11:27.000Z","date":"2017-03-06","kind":"sale","acquired":false,"shares":13576,"price":31.52,"value":427915.52,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices from $31.18 to $32.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":163895,"source":{"system":"sec-edgar","filing":"0001179110-17-004273","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911017004273/edgar.xml","form_type":"4"}},{"id":4430682,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2017-02-23T00:06:00.000Z","date":"2017-02-20","kind":"tax_withholding","acquired":false,"shares":14434,"price":33.78,"value":487580.52,"ownership":{"direct":true},"balance_after":177471,"source":{"system":"sec-edgar","filing":"0001179110-17-002989","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911017002989/edgar.xml","form_type":"4"}},{"id":4461142,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2017-02-09T00:06:41.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":191905,"source":{"system":"sec-edgar","filing":"0001179110-17-001998","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911017001998/edgar.xml","form_type":"4"}},{"id":4544544,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":142307,"kind":"person","name":"HAUMANN BRETT K","position":1,"cik":"0001607733","reported_name":"HAUMANN BRETT K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clin Dev & Chief Med Ofc"}}],"security":"Ordinary Shares","published_at":"2016-11-22T23:02:30.000Z","date":"2016-11-20","kind":"tax_withholding","acquired":false,"shares":5388,"price":31.96,"value":172200.48,"ownership":{"direct":true},"balance_after":182905,"source":{"system":"sec-edgar","filing":"0001179110-16-031976","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911016031976/edgar.xml","form_type":"4"}}]}